• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

25.80 UNCHANGED
Delayed Quote Updated: 4:00 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 397
Open 25.80
Bid (Size) 23.25 (400)
Ask (Size) 30.00 (400)
Prev. Close 25.80
Today's Range 25.80 - 25.80
52wk Range 12.00 - 30.74
Shares Outstanding 144,311,000
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026
October 14, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
September 25, 2026
Definition requires five years off myeloma treatment with sustained MRD negativity, assessed with technology sensitive enough to identify one myeloma cell among one million cells 
From Adaptive Biotechnologies
Via GlobeNewswire

Performance

52-Week Range 16.1% below 52-week high
25.80
12.0052W Low 30.7452W High
1 Week 11.2% below 1-week high
24.801W Low 29.051W High

Adaptive Biotechnologies Corporation - Common Stock (ADPT) traded between $12.00 and $30.74 over the past 52 weeks and last traded at $25.80, 16.1% below its 52-week high. Over the past week it ranged between $24.80 and $29.05.

Past 12 Months
-9.1%
-13.5%
+5.1%
+87.2%
+62.2%
+48.8%
1W -$2.57
1M -$4.04
3M +$1.25
6M +$12.02
YTD +$9.89
1Y +$8.46

ADPT was +48.8% over the past year, +87.2% over six months, +62.2% year to date, -9.1% in the last week.

12 Months vs Market
ADPT
+48.8%
DIA
+9.2%
SPY
+10.4%
QQQ
+8.4%
IWM
+14.0%

Over the past 12 months ADPT returned +48.8% versus DIA (Dow) +9.2%, SPY (S&P 500) +10.4%, QQQ (Nasdaq 100) +8.4% and IWM (Russell 2000) +14.0%.

Volume & Liquidity 0.00× 3-mo avg
Today 397 3-mo avg 2.2M
1W
2.7M
1M
2.0M
3M
2.2M
6M
2.5M
YTD
2.3M
1Y
2.3M

ADPT most recently traded 397 shares against a 3-month average daily volume of 2.2M.

More News

Read More
News headline image
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
September 17, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
September 01, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies (NASDAQ:ADPT) Surges After Q2 Beat and Raised Guidance ↗
July 29, 2026
Via Chartmill
Adaptive Biotechnologies (NASDAQ:ADPT) Surges 6% on Q1 Beat and Raised MRD Guidance ↗
May 05, 2026
Via Chartmill
News headline image
Adaptive Biotechnologies Q2 Earnings Call Highlights ↗
July 29, 2026
Via MarketBeat
Topics Earnings
News headline image
Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
July 29, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run ↗
July 12, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
July 09, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
June 17, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
June 15, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
June 15, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors? ↗
June 14, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference ↗
June 03, 2026
Via MarketBeat
News headline image
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
May 29, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million ↗
May 26, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
May 21, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive (ADPT) Q1 2026 Earnings Transcript ↗
May 06, 2026
Via The Motley Fool
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
May 05, 2026
Via Chartmill
News headline image
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
May 05, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors. ↗
May 04, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means ↗
April 20, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares? ↗
April 18, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
April 15, 2026
From Adaptive Biotechnologies
Via GlobeNewswire

Frequently Asked Questions

Is Adaptive Biotechnologies Corporation - Common Stock publicly traded?
Yes, Adaptive Biotechnologies Corporation - Common Stock is publicly traded.
What exchange does Adaptive Biotechnologies Corporation - Common Stock trade on?
Adaptive Biotechnologies Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Adaptive Biotechnologies Corporation - Common Stock?
The ticker symbol for Adaptive Biotechnologies Corporation - Common Stock is ADPT on the Nasdaq Stock Market
What is the current price of Adaptive Biotechnologies Corporation - Common Stock?
The current price of Adaptive Biotechnologies Corporation - Common Stock is 25.80
When was Adaptive Biotechnologies Corporation - Common Stock last traded?
The last trade of Adaptive Biotechnologies Corporation - Common Stock was at 11/03/26 04:00 PM ET
What is the market capitalization of Adaptive Biotechnologies Corporation - Common Stock?
The market capitalization of Adaptive Biotechnologies Corporation - Common Stock is 3.72B
How many shares of Adaptive Biotechnologies Corporation - Common Stock are outstanding?
Adaptive Biotechnologies Corporation - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap